title: Overview of psychiatric disorders and the role of newer antidepressants.
authors.affiliation: Mood and Anxiety Disorders Research Program, National Institute of Mental Health, Bethesda, MD 20892, USA. charney@nih.gov
authors.forename: Dennis S
authors.initials: DS
authors.lastname: Charney
authors.forename: Dale R
authors.initials: DR
authors.lastname: Grothe
authors.forename: Sherry L
authors.initials: SL
authors.lastname: Smith
authors.forename: Kathleen T
authors.initials: KT
authors.lastname: Brady
authors.forename: Juliana
authors.initials: J
authors.lastname: Kaltsounis-Puckett
authors.forename: Clinton W
authors.initials: CW
authors.lastname: Wright
authors.forename: Lyle K
authors.initials: LK
authors.lastname: Laird
authors.forename: A John
authors.initials: AJ
authors.lastname: Rush
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D003866:Depressive Disorder / Q000188:drug therapy; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D010879:Piperazines; D012893:Sleep Wake Disorders / Q000188:drug therapy; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D014230:Triazoles; C051752:nefazodone